• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

β-淀粉样蛋白聚集在阿尔茨海默病中涉及多种途径:理解其机制。

Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms.

作者信息

Iliyasu Musa O, Musa Sunday A, Oladele Sunday B, Iliya Abdullahi I

机构信息

Department of Anatomy, Kogi State University, Anyigba, Nigeria.

Department of Human Anatomy, Ahmadu Bello University, Zaria, Nigeria.

出版信息

Front Neurosci. 2023 Apr 11;17:1081938. doi: 10.3389/fnins.2023.1081938. eCollection 2023.

DOI:10.3389/fnins.2023.1081938
PMID:37113145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10128090/
Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by tau pathology and accumulations of neurofibrillary tangles (NFTs) along with amyloid-beta (Aβ). It has been associated with neuronal damage, synaptic dysfunction, and cognitive deficits. The current review explained the molecular mechanisms behind the implications of Aβ aggregation in AD multiple events. Beta (β) and gamma (γ) secretases hydrolyzed amyloid precursor protein (APP) to produce Aβ, which then clumps together to form Aβ fibrils. The fibrils increase oxidative stress, inflammatory cascade, and caspase activation to cause hyperphosphorylation of tau protein into neurofibrillary tangles (NFTs), which ultimately lead to neuronal damage. Acetylcholine (Ach) degradation is accelerated by upstream regulation of the acetylcholinesterase (AChE) enzyme, which leads to a deficiency in neurotransmitters and cognitive impairment. There are presently no efficient or disease-modifying medications for AD. It is necessary to advance AD research to suggest novel compounds for treatment and prevention. Prospectively, it might be reasonable to conduct clinical trials with unclean medicines that have a range of effects, including anti-amyloid and anti-tau, neurotransmitter modulation, anti-neuroinflammatory, neuroprotective, and cognitive enhancement.

摘要

阿尔茨海默病(AD)是一种进行性神经退行性疾病,其特征为tau病理变化以及神经原纤维缠结(NFTs)与β淀粉样蛋白(Aβ)的积聚。它与神经元损伤、突触功能障碍和认知缺陷有关。本综述解释了Aβ聚集在AD多个事件中的潜在分子机制。β和γ分泌酶水解淀粉样前体蛋白(APP)以产生Aβ,然后Aβ聚集在一起形成Aβ纤维。这些纤维会增加氧化应激、炎症级联反应和半胱天冬酶激活,从而导致tau蛋白过度磷酸化形成神经原纤维缠结(NFTs),最终导致神经元损伤。乙酰胆碱酯酶(AChE)酶的上游调节加速了乙酰胆碱(Ach)的降解,导致神经递质缺乏和认知障碍。目前尚无治疗AD的有效或疾病修饰药物。推进AD研究以提出用于治疗和预防的新型化合物很有必要。前瞻性地,对具有一系列作用(包括抗淀粉样蛋白和抗tau、神经递质调节、抗神经炎症、神经保护和认知增强)的非洁净药物进行临床试验可能是合理的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/63af4443c3f2/fnins-17-1081938-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/ca28b260f3ef/fnins-17-1081938-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/c9470e9b5b33/fnins-17-1081938-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/b8da217b3b9a/fnins-17-1081938-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/5d582aba7c9c/fnins-17-1081938-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/a7ff5721274c/fnins-17-1081938-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/80401c9f2ffb/fnins-17-1081938-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/63af4443c3f2/fnins-17-1081938-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/ca28b260f3ef/fnins-17-1081938-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/c9470e9b5b33/fnins-17-1081938-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/b8da217b3b9a/fnins-17-1081938-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/5d582aba7c9c/fnins-17-1081938-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/a7ff5721274c/fnins-17-1081938-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/80401c9f2ffb/fnins-17-1081938-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d000/10128090/63af4443c3f2/fnins-17-1081938-g007.jpg

相似文献

1
Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms.β-淀粉样蛋白聚集在阿尔茨海默病中涉及多种途径:理解其机制。
Front Neurosci. 2023 Apr 11;17:1081938. doi: 10.3389/fnins.2023.1081938. eCollection 2023.
2
Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.阿尔茨海默病中针对β淀粉样蛋白的治疗策略
Curr Alzheimer Res. 2019;16(5):418-452. doi: 10.2174/1567205016666190321163438.
3
Alzheimer's disease.阿尔茨海默病
Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14.
4
Neurobiology of Alzheimer's disease.阿尔茨海默病的神经生物学。
Indian J Psychiatry. 2009 Jan;51(1):55-61. doi: 10.4103/0019-5545.44908.
5
Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.植物环烯醚萜类化合物在阿尔茨海默病和帕金森病中的治疗潜力:综述。
Eur J Med Chem. 2019 May 1;169:185-199. doi: 10.1016/j.ejmech.2019.03.009. Epub 2019 Mar 8.
6
Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.茶多酚作为阿尔茨海默病的多靶点治疗药物:一项计算机研究。
Med Hypotheses. 2019 Apr;125:94-99. doi: 10.1016/j.mehy.2019.02.035. Epub 2019 Feb 14.
7
[Alzheimer disease: cellular and molecular aspects].[阿尔茨海默病:细胞与分子层面]
Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1.
8
Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer's disease via inhibiting neuropathology and modulating gut microbiota.纳米厚朴酚通过抑制神经病理学和调节肠道微生物群改善阿尔茨海默病 TgCRND8 小鼠的认知缺陷。
J Adv Res. 2021 Mar 31;35:231-243. doi: 10.1016/j.jare.2021.03.012. eCollection 2022 Jan.
9
Regulation of neuroinflammation in Alzheimer's disease via nanoparticle-loaded phytocompounds with anti-inflammatory and autophagy-inducing properties.通过负载具有抗炎和自噬诱导特性的植物化合物的纳米颗粒调节阿尔茨海默病中的神经炎症。
Phytomedicine. 2024 Jan;122:155150. doi: 10.1016/j.phymed.2023.155150. Epub 2023 Oct 15.
10
Drug candidates in clinical trials for Alzheimer's disease.治疗阿尔茨海默病的临床试验药物候选物。
J Biomed Sci. 2017 Jul 19;24(1):47. doi: 10.1186/s12929-017-0355-7.

引用本文的文献

1
Endogenous Aβ and Exogenous Wheat Gluten Nanostructures: Understanding Peptide Self-Assembly in Disease.内源性淀粉样β蛋白与外源性小麦面筋纳米结构:理解疾病中的肽自组装
ACS Nano. 2025 Sep 2;19(34):30688-30719. doi: 10.1021/acsnano.5c01662. Epub 2025 Aug 8.
2
Sodium benzoate treatment decreased amyloid beta peptides and improved cognitive function among patients with Alzheimer's disease: secondary analysis of a randomized clinical trial.苯甲酸钠治疗可降低阿尔茨海默病患者的β淀粉样肽水平并改善认知功能:一项随机临床试验的二次分析
Transl Psychiatry. 2025 Aug 5;15(1):264. doi: 10.1038/s41398-025-03492-3.
3
Interplay Between Aging and Tau Pathology in Alzheimer's Disease: Mechanisms and Translational Perspectives.

本文引用的文献

1
Alzheimer's disease: natural products as inhibitors of neuroinflammation.阿尔茨海默病:神经炎症抑制剂的天然产物。
Inflammopharmacology. 2020 Dec;28(6):1439-1455. doi: 10.1007/s10787-020-00751-1. Epub 2020 Sep 15.
2
Economic burden of Alzheimer disease and managed care considerations.阿尔茨海默病的经济负担和管理式医疗考虑因素。
Am J Manag Care. 2020 Aug;26(8 Suppl):S177-S183. doi: 10.37765/ajmc.2020.88482.
3
Current and Future Treatments in Alzheimer Disease: An Update.阿尔茨海默病的当前及未来治疗方法:最新进展
阿尔茨海默病中衰老与 Tau 病理的相互作用:机制与转化视角
Antioxidants (Basel). 2025 Jun 24;14(7):774. doi: 10.3390/antiox14070774.
4
Bibliometric analysis of neural injury biomarkers in neurodegenerative diseases: research trends and future perspectives.神经退行性疾病中神经损伤生物标志物的文献计量分析:研究趋势与未来展望
Front Hum Neurosci. 2025 Jun 18;19:1614132. doi: 10.3389/fnhum.2025.1614132. eCollection 2025.
5
Endocytic Pathways Unveil the Role of Syndecans in the Seeding and Spreading of Pathological Protein Aggregates: Insights into Neurodegenerative Disorders.内吞途径揭示了聚糖在病理性蛋白质聚集体的播种和传播中的作用:对神经退行性疾病的见解。
Int J Mol Sci. 2025 Apr 24;26(9):4037. doi: 10.3390/ijms26094037.
6
Neuroprotective potential of hispidulin and diosmin: a review of molecular mechanisms.木犀草素和地奥司明的神经保护潜力:分子机制综述
Metab Brain Dis. 2025 Apr 21;40(5):188. doi: 10.1007/s11011-025-01615-9.
7
Neurostimulation devices to treat Alzheimer's disease.用于治疗阿尔茨海默病的神经刺激设备。
Explor Neurosci. 2025;4. doi: 10.37349/en.2025.100674. Epub 2025 Feb 25.
8
Kaempferia parviflora extract and its methoxyflavones as potential anti-Alzheimer assessing in vitro, integrated computational approach, and in vivo impact on behaviour in scopolamine-induced amnesic mice.山柰提取物及其甲氧基黄酮作为潜在抗阿尔茨海默病药物的体外评估、综合计算方法以及对东莨菪碱诱导的记忆缺失小鼠行为的体内影响
PLoS One. 2025 Mar 10;20(3):e0316888. doi: 10.1371/journal.pone.0316888. eCollection 2025.
9
Ultrasensitive Assays Detect Different Conformations of Plasma β Amyloids.超灵敏检测法可检测血浆β淀粉样蛋白的不同构象。
ACS Omega. 2025 Feb 11;10(7):7256-7263. doi: 10.1021/acsomega.4c10879. eCollection 2025 Feb 25.
10
Aβ induces stress granule formation via PACT/PKR pathway.淀粉样前体蛋白(Aβ)通过PACT/PKR途径诱导应激颗粒形成。
Sci Rep. 2025 Feb 18;15(1):5829. doi: 10.1038/s41598-025-88380-y.
J Cent Nerv Syst Dis. 2020 Feb 29;12:1179573520907397. doi: 10.1177/1179573520907397. eCollection 2020.
4
RyRs mediate lead-induced neurodegenerative disorders through calcium signaling pathways.RyRs 通过钙信号通路介导铅诱导的神经退行性疾病。
Sci Total Environ. 2020 Jan 20;701:134901. doi: 10.1016/j.scitotenv.2019.134901. Epub 2019 Nov 1.
5
The neuropathological diagnosis of Alzheimer's disease.阿尔茨海默病的神经病理学诊断。
Mol Neurodegener. 2019 Aug 2;14(1):32. doi: 10.1186/s13024-019-0333-5.
6
Alzheimer's disease drug development pipeline: 2019.2019年阿尔茨海默病药物研发进程
Alzheimers Dement (N Y). 2019 Jul 9;5:272-293. doi: 10.1016/j.trci.2019.05.008. eCollection 2019.
7
Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders.冰山一角:评估阿尔茨海默病和相关痴呆症的全球社会经济成本及其对利益相关者的战略意义。
J Alzheimers Dis. 2019;70(2):323-341. doi: 10.3233/JAD-190426.
8
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease.阿他贝司他在临床前阿尔茨海默病试验中的初步结果。
N Engl J Med. 2019 Apr 11;380(15):1483-1485. doi: 10.1056/NEJMc1813435.
9
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.随机试验:维鲁贝司他治疗前驱阿尔茨海默病。
N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.
10
Identifying potentially inappropriate prescribing in older people with dementia: a systematic review.识别老年痴呆患者中潜在的不适当处方:一项系统综述。
Eur J Clin Pharmacol. 2019 Apr;75(4):467-481. doi: 10.1007/s00228-018-02612-x. Epub 2019 Jan 4.